 James Douglas Griffin, M.D.
| Title | Professor of Medicine |
|---|
| Institution | Dana-Farber Cancer Institute |
|---|
| Department | Medicine |
|---|
| Address | Dana-Farber Cancer Institute
Mayer 540
44 Binney St
Boston MA 02115
|
|---|
| Phone | 617/632-3360 |
|---|
| Fax | 617/632-2260 |
|---|
|
|
|
 Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N. Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells. PLoS One. 2013; 8(2):e56473.
-
Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL, Frank DA. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012 Jul; 3(7-8):503-11.
-
Guérin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin. 2012 Jul; 28(7):1155-62.
-
Choi HG, Zhang J, Weisberg E, Griffin JD, Sim T, Gray NS. Development of 'DFG-out' inhibitors of gatekeeper mutant kinases. Bioorg Med Chem Lett. 2012 Aug 15; 22(16):5297-302.
-
Deng X, Zhou W, Weisberg E, Wang J, Zhang J, Sasaki T, Nelson E, Griffin JD, Jänne PA, Gray NS. An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRa and kit. Bioorg Med Chem Lett. 2012 Jul 15; 22(14):4579-84.
-
Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011; 6(9):e25351.
-
Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD, Frank DA. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12):3421-9.
-
Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010 Dec; 26(12):2861-9.
-
Weisberg E, Roesel J, Furet P, Bold G, Imbach P, Flörsheimer A, Caravatti G, Jiang J, Manley P, Ray A, Griffin JD. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010 Oct; 1(10):1021-32.
-
Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, Gray NS, Griffin JD. Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther. 2010 Sep; 9(9):2468-77.
-
Chen J, Kesari S, Rooney C, Strack PR, Chen J, Shen H, Wu L, Griffin JD. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer. 2010 Aug; 1(8):822-35.
-
Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, Band H, Carroll M, Reiter A, Larson RA, Salgia R, Griffin JD, Sattler M. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
-
Weisberg E, Deng X, Choi HG, Barrett R, Adamia S, Ray A, Moreno D, Kung AL, Gray N, Griffin JD. Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia. 2010 Jul; 24(7):1375-8.
-
Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley PW, Adamia S, Wu C, Gray N, Griffin JD. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010 May 27; 115(21):4206-16.
-
Jin B, Shen H, Lin S, Li JL, Chen Z, Griffin JD, Wu L. The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival. J Biol Chem. 2010 May 7; 285(19):14356-65.
-
McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
-
Jiang J, Griffin JD. Wnt/ß-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3ß Dependent Manner. Genes Cancer. 2010 Feb; 1(2):164-76.
-
Zhang Y, Askenazi M, Jiang J, Luckey CJ, Griffin JD, Marto JA. A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia. Mol Cell Proteomics. 2010 May; 9(5):780-90.
-
Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 5; 107(1):252-7.
-
Chen J, Imanaka N, Chen J, Griffin JD. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 2010 Jan 19; 102(2):351-60.
-
Sattler M, Griffin JD. JAK2 gets histone H3 rolling. Cancer Cell. 2009 Nov 6; 16(5):365-6.
-
Fernandes MS, Reddy MM, Gonneville JR, DeRoo SC, Podar K, Griffin JD, Weinstock DM, Sattler M. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood. 2009 Aug 27; 114(9):1813-9.
-
Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009 Jun; 12(3):81-9.
-
Smith KA, Griffin JD. Following the cytokine signaling pathway to leukemogenesis: a chronology. J Clin Invest. 2008 Nov; 118(11):3564-73.
-
Weisberg E, Roesel J, Bold G, Furet P, Jiang J, Cools J, Wright RD, Nelson E, Barrett R, Ray A, Moreno D, Hall-Meyers E, Stone R, Galinsky I, Fox E, Gilliland G, Daley JF, Lazo-Kallanian S, Kung AL, Griffin JD. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008 Dec 15; 112(13):5161-70.
-
Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, Adamia S, Stone R, Galinsky I, Kung AL, Griffin JD. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther. 2008 May; 7(5):1121-9.
-
Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008 May 1; 111(9):4788-96.
-
Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008 Apr 1; 111(7):3751-9.
-
Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R, Galinsky I, Fox E, Kung AL, Griffin JD. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood. 2008 Apr 1; 111(7):3723-34.
-
Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007 Dec; 12(6):501-13.
-
Wu L, Maillard I, Nakamura M, Pear WS, Griffin JD. The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development. Blood. 2007 Nov 15; 110(10):3618-23.
-
Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, Zawel L, Tran M, Cools J, Gilliland G, Mitsiades C, McMillin DW, Jiang J, Hall-Meyers E, Griffin JD. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther. 2007 Jul; 6(7):1951-61.
-
Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007 May; 7(5):345-56.
-
Zhao Y, Katzman RB, Delmolino LM, Bhat I, Zhang Y, Gurumurthy CB, Germaniuk-Kurowska A, Reddi HV, Solomon A, Zeng MS, Kung A, Ma H, Gao Q, Dimri G, Stanculescu A, Miele L, Wu L, Griffin JD, Wazer DE, Band H, Band V. The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem. 2007 Apr 20; 282(16):11969-81.
-
Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood. 2007 Jun 1; 109(11):5011-5.
-
Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007 Mar; 117(3):730-8.
-
Chen J, Jette C, Kanki JP, Aster JC, Look AT, Griffin JD. NOTCH1-induced T-cell leukemia in transgenic zebrafish. Leukemia. 2007 Mar; 21(3):462-71.
-
Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, Manley PW, Mestan J, Fabbro D, Jiang J, Hall-Meyers E, Callahan L, DellaGatta JL, Kung AL, Griffin JD. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1; 109(5):2112-20.
-
Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW, Fabbro D, Hall-Meyers E, Catley L, Podar K, Kung AL, Griffin JD. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology. 2006 Dec; 131(6):1734-42.
-
Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15; 354(24):2542-51.
-
Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 Jun 19; 94(12):1765-9.
-
Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K, Griffin JD, Sattler M. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006 Jun 30; 281(26):18177-83.
-
Shen H, McElhinny AS, Cao Y, Gao P, Liu J, Bronson R, Griffin JD, Wu L. The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. Genes Dev. 2006 Mar 15; 20(6):675-88.
-
Sattler M, Walz C, Crowley BJ, Lengfelder E, Jänne PA, Rogers AM, Kuang Y, Distel RJ, Reiter A, Griffin JD. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood. 2006 Feb 1; 107(3):1237-8.
-
Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Moore S, Huntly BJ, Fabbro D, Anderson KC, Griffin JD, Gilliland DG. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005 Dec 15; 24(56):8259-67.
-
Lee BH, Williams IR, Anastasiadou E, Boulton CL, Joseph SW, Amaral SM, Curley DP, Duclos N, Huntly BJ, Fabbro D, Griffin JD, Gilliland DG. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene. 2005 Nov 24; 24(53):7882-92.
-
Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005 Oct 1; 65(19):8968-74.
-
Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005 Nov 15; 106(10):3377-9.
-
Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Okabe R, Fabbro D, Manley PW, Griffin JD, Gilliland DG. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005 Nov 1; 106(9):3206-13.
-
Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005 Jul 1; 11(13):4941-7.
-
Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H, Griffin JD. Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J. 2005 Jul 6; 24(13):2391-402.
-
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97.
-
Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005 Jul 15; 106(2):721-4.
-
Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005 Jun; 19(8):960-2.
-
Griffin JD. Interaction maps for kinase inhibitors. Nat Biotechnol. 2005 Mar; 23(3):308-9.
-
Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Mohammed A, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb; 7(2):129-41.
-
Weisberg E, Catley L, Kujawa J, Atadja P, Remiszewski S, Fuerst P, Cavazza C, Anderson K, Griffin JD. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia. 2004 Dec; 18(12):1951-63.
-
Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005 Feb 15; 105(4):1717-23.
-
Wu L, Griffin JD. Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin Cancer Biol. 2004 Oct; 14(5):348-56.
-
Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Galinsky I, Huntly B, Cohen PS, Meyer T, Fabbro D, Roesel J, Banerji L, Griffin JD, Xiao S, Fletcher JA, Stone RM, Gilliland DG. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Oct 5; 101(40):14479-84.
-
Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, Marynen P, Gilliland DG. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004 Sep 15; 64(18):6385-9.
-
Lin B, Catley L, LeBlanc R, Mitsiades C, Burger R, Tai YT, Podar K, Wartmann M, Chauhan D, Griffin JD, Anderson KC. Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood. 2005 Jan 1; 105(1):350-7.
-
Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005 Jan 1; 105(1):22-30.
-
Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005 Jan 1; 105(1):54-60.
-
Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
-
Chen J, Wall NR, Kocher K, Duclos N, Fabbro D, Neuberg D, Griffin JD, Shi Y, Gilliland DG. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest. 2004 Jun; 113(12):1784-91.
-
Scheijen B, Ngo HT, Kang H, Griffin JD. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene. 2004 Apr 22; 23(19):3338-49.
-
Wu L, Kobayashi K, Sun T, Gao P, Liu J, Nakamura M, Weisberg E, Mukhopadhyay NK, Griffin JD. Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene. Gene. 2004 Mar 17; 328:153-65.
-
Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem. 2004 Mar; 4(3):285-99.
-
Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004 Mar 2; 101(9):3130-5.
-
Gu TL, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, Sternberg DW. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood. 2004 Jun 15; 103(12):4622-9.
-
Okuda K, Sato Y, Sonoda Y, Griffin JD. The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors. Int J Hematol. 2004 Feb; 79(2):138-46.
-
Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol. 2004; 83 Suppl 1:S89-90.
-
Griffin JD. FLT3 tyrosine kinase as a target in acute leukemias. Hematol J. 2004; 5 Suppl 3:S188-90.
-
Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, Drexler HG, Gilliland DG. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2004 Apr 1; 103(7):2802-5.
-
Sawafuji K, Miyakawa Y, Weisberg E, Griffin JD, Ikeda Y, Kizaki M. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. Leuk Lymphoma. 2003 Nov; 44(11):1987-96.
-
Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 1; 63(19):6272-81.
-
Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat. 2003 Oct; 6(5):231-8.
-
Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1; 102(7):2615-22.
-
Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gilliland DG. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell. 2003 May; 3(5):459-69.
-
Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003 Apr; 40(2 Suppl 2):4-10.
-
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14.
-
Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83.
-
Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, O'Neil K, Stover K, El-Naggar A, Griffin JD, Kirsch IR, Kaye FJ. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet. 2003 Feb; 33(2):208-13.
-
Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC, Aster JC. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol. 2003 Jan; 23(2):655-64.
-
Löwenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003; 82-101.
-
Sattler M, Scheijen B, Weisberg E, Griffin JD. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol. 2003; 532:121-40.
-
Wu L, Sun T, Kobayashi K, Gao P, Griffin JD. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol. 2002 Nov; 22(21):7688-700.
-
Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002 Sep 1; 100(5):1532-42.
-
Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 1; 62(17):5019-26.
-
Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002 Nov 15; 100(10):3767-75.
-
Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol. 2002 Jul; 9(4):274-81.
-
Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, Gu H, Griffin JD, Neel BG. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002 Jun; 1(5):479-92.
-
Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin JD. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002 Jun; 1(5):433-43.
-
Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002 May 13; 21(21):3314-33.
-
Liu S, Kiosses WB, Rose DM, Slepak M, Salgia R, Griffin JD, Turner CE, Schwartz MA, Ginsberg MH. A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem. 2002 Jun 7; 277(23):20887-94.
-
Lu Q, Mukhopadhyay NK, Griffin JD, Paredes M, Medina M, Kosik KS. Brain armadillo protein delta-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors. J Neurosci Res. 2002 Mar 1; 67(5):618-24.
-
Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, Salgia R, Lipkowitz S, Griffin JD. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene. 2002 Feb 21; 21(9):1423-33.
-
Griffin JD. Resistance to targeted therapy in leukaemia. Lancet. 2002 Feb 9; 359(9305):458-9.
-
Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15; 99(2):664-71.
-
Griffin JD. Leukemia stem cells and constitutive activation of NF-kappaB. Blood. 2001 Oct 15; 98(8):2291.
-
Chai Y, Wu L, Griffin JD, Paulson HL. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J Biol Chem. 2001 Nov 30; 276(48):44889-97.
-
Bruecher-Encke B, Griffin JD, Neel BG, Lorenz U. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia. 2001 Sep; 15(9):1424-32.
-
Kojika S, Griffin JD. Notch receptors and hematopoiesis. Exp Hematol. 2001 Sep; 29(9):1041-52.
-
Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001 Aug 16; 20(36):5054-8.
-
Griffin JD. Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development. Cancer Chemother Pharmacol. 2001 Aug; 48 Suppl 1:S11-6.
-
Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001 Apr 15; 97(8):2440-8.
-
Griffin JD. Point mutations in the FLT3 gene in AML. Blood. 2001 Apr 15; 97(8):2193A-2193.
-
Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol. 2001 Apr; 73(3):278-91.
-
Griffin JD. Investigator profile: James D. Griffin M.D. interviewed by Vicki P. Glaser. J Hematother Stem Cell Res. 2001 Apr; 10(2):209-14.
-
Weisberg E, Griffin JD. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updat. 2001 Feb; 4(1):22-8.
-
Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000 Dec 15; 275(50):39223-30.
-
Varnum-Finney B, Wu L, Yu M, Brashem-Stein C, Staats S, Flowers D, Griffin JD, Bernstein ID. Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci. 2000 Dec; 113 Pt 23:4313-8.
-
Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet. 2000 Dec; 26(4):484-9.
-
Uemura N, Griffin JD. The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation. Blood. 2000 Nov 1; 96(9):3294-5.
-
Sattler M, Verma S, Pride YB, Salgia R, Rohrschneider LR, Griffin JD. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem. 2001 Jan 26; 276(4):2451-8.
-
Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000 Sep 15; 96(6):2269-76.
-
Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, Greenfield EA, Salgia R, Griffin JD. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000 Aug 11; 275(32):24273-8.
-
Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8.
-
Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000 Jun 1; 95(11):3498-505.
-
Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000 Mar 15; 95(6):2118-25.
-
Shen Y, Lyons P, Cooley M, Davidson D, Veillette A, Salgia R, Griffin JD, Schaller MD. The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo. J Biol Chem. 2000 Jan 14; 275(2):1405-13.
-
Ichinohasama R, Miura I, Takahashi N, Sugawara T, Tamate E, Endoh K, Endoh F, Naganuma H, DeCoteau JF, Griffin JD, Kadin ME, Ooya K. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. Leukemia. 2000 Jan; 14(1):169-82.
-
Uemura N, Griffin JD. The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration. J Biol Chem. 1999 Dec 31; 274(53):37525-32.
-
Thomas JW, Cooley MA, Broome JM, Salgia R, Griffin JD, Lombardo CR, Schaller MD. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem. 1999 Dec 17; 274(51):36684-92.
-
Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, von Andrian UH, Chen LB, Gutierrez-Ramos JC, Pendergast AM, Griffin JD. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999 Dec 15; 94(12):4233-46.
-
Sun Y, Zhang J, Kraeft SK, Auclair D, Chang MS, Liu Y, Sutherland R, Salgia R, Griffin JD, Ferland LH, Chen LB. Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins. J Biol Chem. 1999 Nov 19; 274(47):33522-30.
-
Sattler M, Verma S, Byrne CH, Shrikhande G, Winkler T, Algate PA, Rohrschneider LR, Griffin JD. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol Cell Biol. 1999 Nov; 19(11):7473-80.
-
Vallera DA, Seo SY, Panoskaltsis-Mortari A, Griffin JD, Blazar BR. Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice. Protein Eng. 1999 Sep; 12(9):779-85.
-
Uemura N, Salgia R, Ewaniuk DS, Little MT, Griffin JD. Involvement of the adapter protein CRKL in integrin-mediated adhesion. Oncogene. 1999 Jun 3; 18(22):3343-53.
-
Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, Griffin JD. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999 May 1; 93(9):2928-35.
-
Okuda K, Foster R, Griffin JD. Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Ann N Y Acad Sci. 1999 Apr 30; 872:305-12; discussion 312-3.
-
Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 7; 18(1):67-77.
-
Reed MF, Liu VF, Ladha MH, Ando K, Griffin JD, Weaver DT, Ewen ME. Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation. Oncogene. 1998 Dec 10; 17(23):2961-71.
-
Okuda K, D'Andrea A, Van Etten RA, Griffin JD. The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein. Blood. 1998 Nov 15; 92(10):3848-56.
-
Scammell TE, Griffin JD, Elmquist JK, Saper CB. Microinjection of a cyclooxygenase inhibitor into the anteroventral preoptic region attenuates LPS fever. Am J Physiol. 1998 Mar; 274(3 Pt 2):R783-9.
-
Tong X, Salgia R, Li JL, Griffin JD, Howley PM. The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J Biol Chem. 1997 Dec 26; 272(52):33373-6.
-
Okuda K, Smith L, Griffin JD, Foster R. Signaling functions of the tyrosine residues in the betac chain of the granulocyte-macrophage colony-stimulating factor receptor. Blood. 1997 Dec 15; 90(12):4759-66.
-
Zhao RC, McIvor RS, Griffin JD, Verfaillie CM. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood. 1997 Dec 15; 90(12):4687-98.
-
Hallek M, Neumann C, Schäffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, Druker BJ, Yasukawa K, Griffin JD, Emmerich B. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol. 1997 Dec; 25(13):1367-77.
-
Sattler M, Salgia R, Shrikhande G, Verma S, Choi JL, Rohrschneider LR, Griffin JD. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene. 1997 Nov 6; 15(19):2379-84.
-
Okuda K, D'Andrea A, Etten RA, Griffin JD. A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo. J Clin Invest. 1997 Oct 1; 100(7):1708-15.
-
Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA, Ernst T, Sattler M, Chen LB, Griffin JD. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997 Jul 1; 100(1):46-57.
-
Gu H, Griffin JD, Neel BG. Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells. J Biol Chem. 1997 Jun 27; 272(26):16421-30.
-
Sattler M, Salgia R, Shrikhande G, Verma S, Uemura N, Law SF, Golemis EA, Griffin JD. Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem. 1997 May 30; 272(22):14320-6.
-
Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV, Griffin JD. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem. 1997 Apr 11; 272(15):10248-53.
-
Sattler M, Salgia R, Durstin MA, Prasad KV, Griffin JD. Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol. 1997 Apr; 171(1):28-33.
-
Boulant JA, Chow AR, Griffin JD. Determinants of hypothalamic neuronal thermosensitivity. Ann N Y Acad Sci. 1997 Mar 15; 813:133-8.
-
Uemura N, Salgia R, Li JL, Pisick E, Sattler M, Griffin JD. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia. 1997 Mar; 11(3):376-85.
-
Manié SN, Beck AR, Astier A, Law SF, Canty T, Hirai H, Druker BJ, Avraham H, Haghayeghi N, Sattler M, Salgia R, Griffin JD, Golemis EA, Freedman AS. Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem. 1997 Feb 14; 272(7):4230-6.
-
Manié SN, Sattler M, Astier A, Phifer JS, Canty T, Morimoto C, Druker BJ, Salgia R, Griffin JD, Freedman AS. Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. Exp Hematol. 1997 Jan; 25(1):45-50.
-
Salgia R, Avraham S, Pisick E, Li JL, Raja S, Greenfield EA, Sattler M, Avraham H, Griffin JD. The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem. 1996 Dec 6; 271(49):31222-6.
-
Xia K, Mukhopadhyay NK, Inhorn RC, Barber DL, Rose PE, Lee RS, Narsimhan RP, D'Andrea AD, Griffin JD, Roberts TM. The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11681-6.
-
Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996 Oct 11; 271(41):25198-203.
-
Scammell TE, Elmquist JK, Griffin JD, Saper CB. Ventromedial preoptic prostaglandin E2 activates fever-producing autonomic pathways. J Neurosci. 1996 Oct 1; 16(19):6246-54.
-
Okuda K, Golub TR, Gilliland DG, Griffin JD. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 1996 Sep 19; 13(6):1147-52.
-
Durstin M, Inhorn RC, Griffin JD. Tyrosine phosphorylation of Shc is not required for proliferation or viability signaling by granulocyte-macrophage colony-stimulating factor in hematopoietic cell lines. J Immunol. 1996 Jul 15; 157(2):534-40.
-
Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest. 1996 Jul 15; 98(2):521-8.
-
Hallek M, Danhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb HJ, Druker B, Griffin JD, Emmerich B, Ullrich A. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol. 1996 Jul; 94(1):5-16.
-
Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996 Mar 1; 183(3):811-20.
-
Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996 Feb 15; 12(4):839-46.
-
Salgia R, Sattler M, Pisick E, Li JL, Griffin JD. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol. 1996 Feb; 24(2):310-3.
-
Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol. 1996 Feb 1; 156(3):1126-31.
-
Salgia R, Brunkhorst B, Pisick E, Li JL, Lo SH, Chen LB, Griffin JD. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 1995 Sep 21; 11(6):1149-55.
-
Inhorn RC, Carlesso N, Durstin M, Frank DA, Griffin JD. Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750. Proc Natl Acad Sci U S A. 1995 Sep 12; 92(19):8665-9.
-
Sattler M, Durstin MA, Frank DA, Okuda K, Kaushansky K, Salgia R, Griffin JD. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.
-
Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995 May 1; 85(9):2507-15.
-
Davey FR, Abraham N, Brunetto VL, MacCallum JM, Nelson DA, Ball ED, Griffin JD, Baer MR, Wurster-Hill D, Mayer RJ, et al. Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study. Am J Hematol. 1995 May; 49(1):29-38.
-
Drachman JG, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem. 1995 Mar 10; 270(10):4979-82.
-
Ando K, Griffin JD. Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. Oncogene. 1995 Feb 16; 10(4):751-5.
-
Oda T, Tamura S, Matsuguchi T, Griffin JD, Druker BJ. The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. Leukemia. 1995 Feb; 9(2):295-301.
-
Matsuguchi T, Inhorn RC, Carlesso N, Xu G, Druker B, Griffin JD. Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. EMBO J. 1995 Jan 16; 14(2):257-65.
-
Eder M, Ernst TJ, Ganser A, Jubinsky PT, Inhorn R, Hoelzer D, Griffin JD. A low affinity chimeric human alpha/beta-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line. J Biol Chem. 1994 Dec 2; 269(48):30173-80.
-
Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG, Nadler LM. CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. J Exp Med. 1994 Nov 1; 180(5):1665-73.
-
Okuda K, Ernst TJ, Griffin JD. Inhibition of p21ras activation blocks proliferation but not differentiation of interleukin-3-dependent myeloid cells. J Biol Chem. 1994 Oct 7; 269(40):24602-7.
-
Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol. 1994 Oct; 22(11):1111-7.
-
Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994 Sep 16; 269(37):22925-8.
-
Avalos BR, Broudy VC, Ceselski SK, Druker BJ, Griffin JD, Hammond WP. Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression. Blood. 1994 Aug 1; 84(3):789-94.
-
Quelle FW, Sato N, Witthuhn BA, Inhorn RC, Eder M, Miyajima A, Griffin JD, Ihle JN. JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol. 1994 Jul; 14(7):4335-41.
-
Hallek M, Ando K, Eder M, Slattery K, Ajchenbaum-Cymbalista F, Griffin JD. Signal transduction of steel factor and granulocyte-macrophage colony-stimulating factor: differential regulation of transcription factor and G1 cyclin gene expression, and of proliferation in the human factor-dependent cell line MO7. Leukemia. 1994 May; 8(5):740-8.
-
Matulonis UA, Griffin JD, Canellos GP. Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. Am J Hematol. 1994 Apr; 45(4):283-7.
-
Ernst TJ, Slattery KE, Griffin JD. p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J Biol Chem. 1994 Feb 25; 269(8):5764-9.
-
Druker BJ, Neumann M, Okuda K, Franza BR, Griffin JD. rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils. J Biol Chem. 1994 Feb 18; 269(7):5387-90.
-
Matsuguchi T, Salgia R, Hallek M, Eder M, Druker B, Ernst TJ, Griffin JD. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem. 1994 Feb 18; 269(7):5016-21.
-
Carlesso N, Griffin JD, Druker BJ. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene. 1994 Jan; 9(1):149-56.
-
Ando K, Ajchenbaum-Cymbalista F, Griffin JD. Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci U S A. 1993 Oct 15; 90(20):9571-5.
-
Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993 Oct; 21(11):1460-6.
-
Robertson MJ, Tantravahi R, Griffin JD, Canellos GP, Cannistra SA. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol. 1993 Jun; 43(2):95-102.
-
Eder M, Griffin JD, Ernst TJ. The human granulocyte-macrophage colony-stimulating factor receptor is capable of initiating signal transduction in NIH3T3 cells. EMBO J. 1993 Apr; 12(4):1647-56.
-
Ajchenbaum F, Ando K, DeCaprio JA, Griffin JD. Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem. 1993 Feb 25; 268(6):4113-9.
-
Hallek M, Druker B, Lepisto EM, Wood KW, Ernst TJ, Griffin JD. Granulocyte-macrophage colony-stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor-dependent hematopoietic cell line. J Cell Physiol. 1992 Oct; 153(1):176-86.
-
Hallek M, Lepisto EM, Slattery KE, Griffin JD, Ernst TJ. Interferon-gamma increases the expression of the gene encoding the beta subunit of the granulocyte-macrophage colony-stimulating factor receptor. Blood. 1992 Oct 1; 80(7):1736-42.
-
Furukawa Y, Uenoyama S, Ohta M, Tsunoda A, Griffin JD, Saito M. Transforming growth factor-beta inhibits phosphorylation of the retinoblastoma susceptibility gene product in human monocytic leukemia cell line JOSK-I. J Biol Chem. 1992 Aug 25; 267(24):17121-7.
-
Gribben JG, Saporito L, Barber M, Blake KW, Edwards RM, Griffin JD, Freedman AS, Nadler LM. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood. 1992 Aug 15; 80(4):1083-9.
-
Okuda K, Sanghera JS, Pelech SL, Kanakura Y, Hallek M, Griffin JD, Druker BJ. Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood. 1992 Jun 1; 79(11):2880-7.
-
Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Griffin JD, Nadler LM, et al. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 1992 May 1; 79(9):2229-36.
-
Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood. 1992 May 1; 79(9):2215-20.
-
La Russa VF, Griffin JD, Kessler SW, Cutting MA, Knight RD, Blattler WA, Lambert JM, Wright DG. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp Hematol. 1992 May; 20(4):442-8.
-
DeCaprio JA, Furukawa Y, Ajchenbaum F, Griffin JD, Livingston DM. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci U S A. 1992 Mar 1; 89(5):1795-8.
-
Ishida Y, Furukawa Y, Decaprio JA, Saito M, Griffin JD. Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose. J Cell Physiol. 1992 Mar; 150(3):484-92.
-
Tamaki T, Kanakura Y, Kuriu A, Ikeda H, Mitsui H, Yagura H, Matsumura I, Druker B, Griffin JD, Kanayama Y, et al. Surface immunoglobulin-mediated signal transduction involves rapid phosphorylation and activation of the protooncogene product Raf-1 in human B-cells. Cancer Res. 1992 Feb 1; 52(3):566-70.
-
Koenigsmann M, Griffin JD, DiCarlo J, Cannistra SA. Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. Blood. 1992 Feb 1; 79(3):657-65.
-
Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991 Dec 1; 78(11):2962-8.
-
Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991 Dec 1; 78(11):2791-808.
-
Kuriu A, Ikeda H, Kanakura Y, Griffin JD, Druker B, Yagura H, Kitayama H, Ishikawa J, Nishiura T, Kanayama Y, et al. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. Blood. 1991 Dec 1; 78(11):2834-40.
-
Spertini O, Luscinskas FW, Kansas GS, Munro JM, Griffin JD, Gimbrone MA, Tedder TF. Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. J Immunol. 1991 Oct 15; 147(8):2565-73.
-
Okuda K, Druker B, Kanakura Y, Koenigsmann M, Griffin JD. Internalization of the granulocyte-macrophage colony-stimulating factor receptor is not required for induction of protein tyrosine phosphorylation in human myeloid cells. Blood. 1991 Oct 15; 78(8):1928-35.
-
Shipp MA, Stefano GB, Switzer SN, Griffin JD, Reinherz EL. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood. 1991 Oct 1; 78(7):1834-41.
-
Furukawa Y, DeCaprio JA, Belvin M, Griffin JD. Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene. 1991 Aug; 6(8):1343-6.
-
Roy DC, Griffin JD, Belvin M, Blättler WA, Lambert JM, Ritz J. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood. 1991 Jun 1; 77(11):2404-12.
-
Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, Wurster-Hill D, Noll W, Elghetany MT, Allen SL, et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991 May 15; 77(10):2242-50.
-
Spertini O, Freedman AS, Belvin MP, Penta AC, Griffin JD, Tedder TF. Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia. 1991 Apr; 5(4):300-8.
-
Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia. 1991 Mar; 5(3):230-8.
-
Kanakura Y, Cannistra SA, Brown CB, Nakamura M, Seelig GF, Prosise WW, Hawkins JC, Kaushansky K, Griffin JD. Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. Blood. 1991 Mar 1; 77(5):1033-43.
-
Spertini O, Kansas GS, Munro JM, Griffin JD, Tedder TF. Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature. 1991 Feb 21; 349(6311):691-4.
-
Kanakura Y, Druker B, Wood KW, Mamon HJ, Okuda K, Roberts TM, Griffin JD. Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce rapid phosphorylation and activation of the proto-oncogene Raf-1 in a human factor-dependent myeloid cell line. Blood. 1991 Jan 15; 77(2):243-8.
-
Kanakura Y, Druker B, DiCarlo J, Cannistra SA, Griffin JD. Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line. J Biol Chem. 1991 Jan 5; 266(1):490-5.
-
Furukawa Y, Piwnica-Worms H, Ernst TJ, Kanakura Y, Griffin JD. cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science. 1990 Nov 9; 250(4982):805-8.
-
Demetri GD, Ernst TJ, Pratt ES, Zenzie BW, Rheinwald JG, Griffin JD. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J Clin Invest. 1990 Oct; 86(4):1261-9.
-
Sharkis SJ, Jones RJ, Bellis ML, Demetri GD, Griffin JD, Civin C, May WS. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood. 1990 Aug 15; 76(4):716-20.
-
Kanakura Y, Druker B, Cannistra SA, Furukawa Y, Torimoto Y, Griffin JD. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood. 1990 Aug 15; 76(4):706-15.
-
Cannistra SA, Koenigsmann M, DiCarlo J, Groshek P, Griffin JD. Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells. J Biol Chem. 1990 Jul 25; 265(21):12656-63.
-
Griffin JD, Spertini O, Ernst TJ, Belvin MP, Levine HB, Kanakura Y, Tedder TF. Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J Immunol. 1990 Jul 15; 145(2):576-84.
-
Nakamura M, Kanakura Y, Furukawa Y, Ernst TJ, Griffin JD. Demonstration of interleukin-1 beta transcripts in acute myeloblastic leukemic cells by in situ hybridization. Leukemia. 1990 Jul; 4(7):466-70.
-
Demetri GD, Griffin JD. Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail? J Clin Oncol. 1990 May; 8(5):761-4.
-
Furukawa Y, DeCaprio JA, Freedman A, Kanakura Y, Nakamura M, Ernst TJ, Livingston DM, Griffin JD. Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci U S A. 1990 Apr; 87(7):2770-4.
-
Griffin JD, Demetri GD, Kanakura Y, Cannistra SA, Ernst TJ. Cellular interaction regulating the production of colony-stimulating factors. Prog Clin Biol Res. 1990; 338:129-41.
-
Cannistra SA, Groshek P, Garlick R, Miller J, Griffin JD. Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):93-7.
-
Griffin JD, Cannistra SA, Sullivan R, Demetri GD, Ernst TJ, Kanakura Y. The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning. 1990 Jan; 8 Suppl 1:35-44; discussion 44-5.
-
Nakamura M, Merchav S, Carter A, Ernst TJ, Demetri GD, Furukawa Y, Anderson K, Freedman AS, Griffin JD. Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol. 1989 Dec 1; 143(11):3543-7.
-
Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G. Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res. 1989 Nov 1; 56(3):425-30.
-
Ernst TJ, Ritchie AR, O'Rourke R, Griffin JD. Colony-stimulating factor gene expression in human acute myeloblastic leukemia cells is posttranscriptionally regulated. Leukemia. 1989 Sep; 3(9):620-5.
-
Demetri GD, Griffin JD. Hemopoietins and leukemia. Hematol Oncol Clin North Am. 1989 Sep; 3(3):535-53.
-
Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood. 1989 Aug 15; 74(3):940-6.
-
Keinänen M, Bloomfield CD, Machnicki J, Griffin JD, de la Chapelle A. Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages. Leukemia. 1989 Jun; 3(6):405-12.
-
Ball ED, McDermott J, Griffin JD, Davey FR, Davis R, Bloomfield CD. Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. Blood. 1989 May 15; 73(7):1951-6.
-
Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia. 1989 May; 3(5):328-34.
-
Sullivan R, Fredette JP, Leavitt JL, Gadenne AS, Griffin JD, Simons ER. Effects of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSFrh) on transmembrane electrical potentials in granulocytes: relationship between enhancement of ligand-mediated depolarization and augmentation of superoxide anion (O2-) production. J Cell Physiol. 1989 May; 139(2):361-9.
-
Sullivan R, Fredette JP, Griffin JD, Leavitt JL, Simons ER, Melnick DA. An elevation in the concentration of free cytosolic calcium is sufficient to activate the oxidative burst of granulocytes primed with recombinant human granulocyte-macrophage colony-stimulating factor. J Biol Chem. 1989 Apr 15; 264(11):6302-9.
-
Ernst TJ, Ritchie AR, Demetri GD, Griffin JD. Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. J Biol Chem. 1989 Apr 5; 264(10):5700-3.
-
Sullivan R, Fredette JP, Socinski M, Elias A, Antman K, Schnipper L, Griffin JD. Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor. Br J Haematol. 1989 Apr; 71(4):475-9.
-
Davey FR, Davis RB, MacCallum JM, Nelson DA, Mayer RJ, Ball ED, Griffin JD, Schiffer CA, Bloomfield CD. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol. 1989 Apr; 30(4):221-7.
-
Griffin JD. Hemopoietins in oncology: factoring out myelosuppression. J Clin Oncol. 1989 Feb; 7(2):151-5.
-
Rosmarin AG, Weil SC, Rosner GL, Griffin JD, Arnaout MA, Tenen DG. Differential expression of CD11b/CD18 (Mo1) and myeloperoxidase genes during myeloid differentiation. Blood. 1989 Jan; 73(1):131-6.
-
Herrmann F, Lindemann A, Cannistra SA, Brach M, Oster W, Griffin JD, Mertelsmann R. Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 receptors. Haematol Blood Transfus. 1989; 32:299-315.
-
Holland CA, Rothstein L, Sakakeeny MA, Anklesaria P, Griffin JD, Harigaya K, Newburger PE, Greenberger JS. Infection of hematopoietic and stromal cells in human continuous bone marrow cultures by a retroviral vector containing the neomycin resistance gene. Acta Haematol. 1989; 82(3):136-43.
-
Chang HC, Hsu F, Freeman GJ, Griffin JD, Reinherz EL. Cloning and expression of a gamma-interferon-inducible gene in monocytes: a new member of a cytokine gene family. Int Immunol. 1989; 1(4):388-97.
-
Ernst TJ, Griffin JD. Regulation of colony-stimulating factor production by normal and leukemic human cells. Immunol Res. 1989; 8(3):202-14.
-
Herrmann F, Cannistra SA, Lindemann A, Blohm D, Rambaldi A, Mertelsmann RH, Griffin JD. Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. J Immunol. 1989 Jan 1; 142(1):139-43.
-
Ernst TJ, Rosenthal DS, Griffin JD, Canellos GP. Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. Am J Clin Oncol. 1988 Dec; 11(6):623-6.
-
Cannistra SA, Groshek P, Griffin JD. Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor. Exp Hematol. 1988 Nov; 16(10):865-70.
-
Sullivan R, Griffin JD, Wright J, Melnick DA, Leavitt JL, Fredette JP, Horne JH, Lyman CA, Lazzari KG, Simons ER. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on intracellular pH in mature granulocytes. Blood. 1988 Nov; 72(5):1665-73.
-
Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 8; 319(10):593-8.
-
Socinski MA, Cannistra SA, Sullivan R, Elias A, Antman K, Schnipper L, Griffin JD. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. Blood. 1988 Aug; 72(2):691-7.
-
Wang JM, Griffin JD, Rambaldi A, Chen ZG, Mantovani A. Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol. 1988 Jul 15; 141(2):575-9.
-
Cannistra SA, Griffin JD. Regulation of the production and function of granulocytes and monocytes. Semin Hematol. 1988 Jul; 25(3):173-88.
-
Vellenga E, Rambaldi A, Ernst TJ, Ostapovicz D, Griffin JD. Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood. 1988 Jun; 71(6):1529-32.
-
Young DC, Demetri GD, Ernst TJ, Cannistra SA, Griffin JD. In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells. Exp Hematol. 1988 Jun; 16(5):378-82.
-
Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28; 1(8596):1194-8.
-
Keinänen M, Griffin JD, Bloomfield CD, Machnicki J, de la Chapelle A. Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. N Engl J Med. 1988 May 5; 318(18):1153-8.
-
Herrmann F, Griffin JD, Sabbath KD, Oster W, Wernet P, Mertelsmann R. Identification and purification of human erythroid progenitor cells by monoclonal antibody to the transferrin receptor (TU 67). Blut. 1988 Apr; 56(4):179-83.
-
Rambaldi A, Wakamiya N, Vellenga E, Horiguchi J, Warren MK, Kufe D, Griffin JD. Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest. 1988 Apr; 81(4):1030-5.
-
Cannistra SA, Vellenga E, Groshek P, Rambaldi A, Griffin JD. Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood. 1988 Mar; 71(3):672-6.
-
Simpson PJ, Todd RF, Fantone JC, Mickelson JK, Griffin JD, Lucchesi BR. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest. 1988 Feb; 81(2):624-9.
-
Griffin JD. Clinical applications of colony-stimulating factors. Oncology (Williston Park). 1988 Jan; 2(1):15-23.
-
Vellenga E, Griffin JD. The biology of acute myeloblastic leukemia. Semin Oncol. 1987 Dec; 14(4):365-71.
-
Sullivan R, Griffin JD, Simons ER, Schafer AI, Meshulam T, Fredette JP, Maas AK, Gadenne AS, Leavitt JL, Melnick DA. Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. J Immunol. 1987 Nov 15; 139(10):3422-30.
-
Griffin JD. Growth factors required for proliferation of clonogenic cells in acute myeloblastic leukemia (AML). Haematologica. 1987 Nov-Dec; 72(6 Suppl):85-8.
-
Griffin JD, Rambaldi A, Vellenga E, Young DC, Ostapovicz D, Cannistra SA. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987 Oct; 70(4):1218-21.
-
Sullivan R, Griffin JD, Malech HL. Acquisition of formyl peptide receptors during normal human myeloid differentiation. Blood. 1987 Oct; 70(4):1222-4.
-
Vellenga E, Ostapovicz D, O'Rourke B, Griffin JD. Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia. 1987 Aug; 1(8):584-9.
-
Kufe DW, Spriggs DR, Griffin JD. Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside. Semin Oncol. 1987 Jun; 14(2 Suppl 1):149-58.
-
Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood. 1987 Jun; 69(6):1771-6.
-
Cannistra SA, Rambaldi A, Spriggs DR, Herrmann F, Kufe D, Griffin JD. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest. 1987 Jun; 79(6):1720-8.
-
Boyd AW, Tedder TF, Griffin JD, Freedman AS, Fisher DC, Daley J, Nadler LM. Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals. Cell Immunol. 1987 May; 106(2):355-65.
-
Rambaldi A, Young DC, Griffin JD. Expression of the M-CSF (CSF-1) gene by human monocytes. Blood. 1987 May; 69(5):1409-13.
-
Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner J, Griffin JD, Collins H, Nelson DA, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987 Apr 30; 316(18):1111-7.
-
Band H, Corredor V, Lustgarten J, Huebner K, Griffin JD, Kufe DW, Yunis EJ. Southern blot analysis of BII cell line--a putative variant of HL-60. Leukemia. 1987 Feb; 1(2):142-5.
-
Sullivan R, Melnick DA, Malech HL, Meshulam T, Simons ER, Lazzari KG, Proto PJ, Gadenne AS, Leavitt JL, Griffin JD. The effects of phorbol myristate acetate and chemotactic peptide on transmembrane potentials and cytosolic free calcium in mature granulocytes evolve sequentially as the cells differentiate. J Biol Chem. 1987 Jan 25; 262(3):1274-81.
-
Herrmann F, Schmidt RE, Ritz J, Griffin JD. In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. Blood. 1987 Jan; 69(1):246-54.
-
Herrmann F, Oster W, Lindemann A, Ganser A, Dörken B, Knapp W, Griffin JD, Mertelsmann R. Leukemic colony-forming cells in acute myeloblastic leukemia: maturation hierarchy and growth conditions. Haematol Blood Transfus. 1987; 31:185-90.
-
Griffin JD. The use of monoclonal antibodies in the characterization of myeloid leukemias. Hematol Pathol. 1987; 1(2):81-91.
-
Rambaldi A, Young DC, Herrmann F, Cannistra SA, Griffin JD. Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. Eur J Immunol. 1987 Jan; 17(1):153-6.
-
Young DC, Wagner K, Griffin JD. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J Clin Invest. 1987 Jan; 79(1):100-6.
-
Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer C, McIntyre OR, Bloomfield CD. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood. 1986 Dec; 68(6):1232-41.
-
Griffin JD, Löwenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood. 1986 Dec; 68(6):1185-95.
-
Dana N, Styrt B, Griffin JD, Todd RF, Klempner MS, Arnaout MA. Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J Immunol. 1986 Nov 15; 137(10):3259-63.
-
Young DC, Griffin JD. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood. 1986 Nov; 68(5):1178-81.
-
Griffin JD, Young DC. The role of colony stimulating factors in leukaemogenesis. Clin Haematol. 1986 Nov; 15(4):995-1002.
-
Messner HA, Griffin JD. Biology of acute myeloid leukaemia. Clin Haematol. 1986 Aug; 15(3):641-67.
-
Griffin JD. Management of chronic myelogenous leukemia. Semin Hematol. 1986 Jul; 23(3 Suppl 1):20-6.
-
Griffin JD, Young D, Herrmann F, Wiper D, Wagner K, Sabbath KD. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood. 1986 May; 67(5):1448-53.
-
Herrmann F, Cannistra SA, Griffin JD. T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro. J Immunol. 1986 Apr 15; 136(8):2856-61.
-
Hokland P, Kerndrup G, Griffin JD, Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood. 1986 Apr; 67(4):898-902.
-
Herrmann F, Griffin JD, Meuer SG, Meyer zum Büschenfelde KH. Establishment of an interleukin 2-dependent T cell line derived from a patient with severe aplastic anemia, which inhibits in vitro hematopoiesis. J Immunol. 1986 Mar 1; 136(5):1629-34.
-
Cannistra SA, Herrmann F, Davis R, Nichols K, Griffin JD. Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistance in chronic myeloid leukemia. J Clin Invest. 1986 Jan; 77(1):13-20.
-
Picus J, Holley K, Aldrich WR, Griffin JD, Letvin NL. A naturally occurring bone marrow-chimeric primate. II. Environment dictates restriction on cytolytic T lymphocyte-target cell interactions. J Exp Med. 1985 Dec 1; 162(6):2035-52.
-
Griffin JD, Larcom P, Kufe DW. TPA induces differentiation of purified human myeloblasts in the absence of proliferation. Exp Hematol. 1985 Nov; 13(10):1025-32.
-
Avnstrøm S, Plesner T, Ralfkier E, Wilken M, Griffin JD, Nissen NI. Expression of an antigen defined by a monoclonal antibody (SA-1) on normal and malignant cells. Scand J Haematol. 1985 Oct; 35(4):408-17.
-
Griffin JD, Sabbath KD, Herrmann F, Larcom P, Nichols K, Kornacki M, Levine H, Cannistra SA. Differential expression of HLA-DR antigens in subsets of human CFU-GM. Blood. 1985 Oct; 66(4):788-95.
-
Sabbath KD, Griffin JD. Clonogenic cells in acute myeloblastic leukaemia. Scand J Haematol. 1985 Sep; 35(3):251-6.
-
Herrmann F, Cannistra SA, Levine H, Griffin JD. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med. 1985 Sep 1; 162(3):1111-6.
-
Canellos GP, Griffin JD. Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity. Semin Oncol. 1985 Sep; 12(3):281-8.
-
Boyd AW, Griffin JD. Detection of nonrandom clustering of colonies in agar culture. Exp Hematol. 1985 Aug; 13(7):696-700.
-
Matutes E, Rodriguez B, Polli N, Tavares de Castro J, Parreira A, Andrews C, Griffin JD, Tindle RW, Catovsky D. Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9. Hematol Oncol. 1985 Jul-Sep; 3(3):179-86.
-
Griffin JD, Spriggs D, Wisch JS, Kufe DW. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. J Clin Oncol. 1985 Jul; 3(7):982-91.
-
Griffin JD, Maguire ME, Mayer RJ. Amsacrine in refractory acute leukemia. Cancer Treat Rep. 1985 Jul-Aug; 69(7-8):787-9.
-
Biondi A, Roach JA, Griffin JD, Todd RF. Mb1, a plasma membrane antigen selectively expressed by U-937 cells. Blood. 1985 Jul; 66(1):135-42.
-
Koizumi S, Fine RL, Curt GA, Griffin JD, Chabner BA. Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique. Exp Hematol. 1985 Jul; 13(6):560-5.
-
Kufe DW, Griffin JD, Spriggs DR. Cellular and clinical pharmacology of low-dose ara-C. Semin Oncol. 1985 Jun; 12(2 Suppl 3):200-7.
-
Mabry M, Speak JA, Griffin JD, Stahel RA, Bernal SD. Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. J Clin Invest. 1985 May; 75(5):1690-5.
-
Hercend T, Griffin JD, Bensussan A, Schmidt RE, Edson MA, Brennan A, Murray C, Daley JF, Schlossman SF, Ritz J. Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest. 1985 Mar; 75(3):932-43.
-
Koizumi S, Curt GA, Fine RL, Griffin JD, Chabner BA. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest. 1985 Mar; 75(3):1008-14.
-
Bernal SD, Mabry M, Stahel RA, Griffin JD, Speak JA. Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung. Cancer Res. 1985 Mar; 45(3):1026-32.
-
Cannistra SA, Daley JF, Larcom P, Griffin JD. Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells. Blood. 1985 Feb; 65(2):414-22.
-
Sabbath KD, Ball ED, Larcom P, Davis RB, Griffin JD. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest. 1985 Feb; 75(2):746-53.
-
Shkolnik T, Schlossman SF, Griffin JD. Acute undifferentiated leukemia: induction of partial differentiation by phorbol ester. Leuk Res. 1985; 9(1):11-7.
-
Hokland P, Nadler LM, Griffin JD, Schlossman SF, Ritz J. Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood. 1984 Sep; 64(3):662-6.
-
Griffin JD, Sullivan R, Beveridge RP, Larcom P, Schlossman SF. Induction of proliferation of purified human myeloid progenitor cells: a rapid assay for granulocyte colony-stimulating factors. Blood. 1984 Apr; 63(4):904-11.
-
Tantravahi R, Schwenn M, Henkle C, Nell M, Leavitt PR, Griffin JD, Weinstein HJ. A pericentric inversion of chromosome 16 is associated with dysplastic marrow eosinophils in acute myelomonocytic leukemia. Blood. 1984 Apr; 63(4):800-2.
-
Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984; 8(4):521-34.
-
Wisch JS, Griffin JD, Kufe DW. Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med. 1983 Dec 29; 309(26):1599-602.
-
Griffin JD, Larcom P, Schlossman SF. Use of surface markers to identify a subset of acute myelomonocytic leukemia cells with progenitor cell properties. Blood. 1983 Dec; 62(6):1300-3.
-
Tantravahi R, Griffin JD, Henkle C, Leavitt PR, Mayer RJ, Frei E. Immunological and cytogenetic studies in two cases of B-cell acute lymphoblastic leukemia (Burkitt's type). Cancer Genet Cytogenet. 1983 Oct; 10(2):167-75.
-
Schnitzer B, Lovett EJ, Flint A, Hudson JL, Kahn LE, Bricker LJ, Griffin JD. Microgranular acute promyelocytic leukemia diagnosed by flow cytometry. N Engl J Med. 1983 Aug 18; 309(7):435.
-
Anderson KC, Griffin JD, Bates MP, Slaughenhoupt BL, Schlossman SF, Nadler LM. Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion. J Immunol Methods. 1983 Jul 29; 61(3):283-92.
-
Rosenthal P, Rimm IJ, Umiel T, Griffin JD, Osathanondh R, Schlossman SF, Nadler LM. Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol. 1983 Jul; 131(1):232-7.
-
Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J Immunol. 1983 Jun; 130(6):2947-51.
-
Garnick MB, Griffin JD. Idiopathic thrombocytopenia in association with extragonadal germ cell cancer. Ann Intern Med. 1983 Jun; 98(6):926-7.
-
Griffin JD, Ritz J, Beveridge RP, Lipton JM, Daley JF, Schlossman SF. Expression of MY7 antigen on myeloid precursor cells. Int J Cell Cloning. 1983 Apr; 1(1):33-48.
-
Griffin JD, Tantravahi R, Canellos GP, Wisch JS, Reinherz EL, Sherwood G, Beveridge RP, Daley JF, Lane H, Schlossman SF. T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. Blood. 1983 Apr; 61(4):640-4.
-
Letvin NL, Todd RF, Palley LS, Schlossman SF, Griffin JD. Conservation of myeloid surface antigens on primate granulocytes. Blood. 1983 Feb; 61(2):408-10.
-
Griffin JD, Beveridge RP, Schlossman SF. Effect of phorbol ester on differentiation of human myeloid colony forming cells (CFU-C). Leuk Res. 1983; 7(1):43-9.
-
Griffin JD, Todd RF, Ritz J, Nadler LM, Canellos GP, Rosenthal D, Gallivan M, Beveridge RP, Weinstein H, Karp D, Schlossman SF. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91.
-
Weiss RB, Moquin D, Adams JD, Griffin JD, Zimbler H. Electrocardiogram abnormalities induced by amsacrine. Cancer Chemother Pharmacol. 1983; 10(2):133-4.
-
Hokland P, Rosenthal P, Griffin JD, Nadler LM, Daley J, Hokland M, Schlossman SF, Ritz J. Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med. 1983 Jan 1; 157(1):114-29.
-
Griffin JD, Beveridge RP, Schlossman SF. Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients. Blood. 1982 Jul; 60(1):30-7.
-
Bradley MK, Griffin JD, Livingston DM. Relationship of oligomerization to enzymatic and DNA-binding properties of the SV40 large T antigen. Cell. 1982 Jan; 28(1):125-34.
-
Griffin JD, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest. 1981 Oct; 68(4):932-41.
-
Griffin JD, Garnick MB. Eye toxicity of cancer chemotherapy: a review of the literature. Cancer. 1981 Oct 1; 48(7):1539-49.
-
Nadler LM, Ritz J, Griffin JD, Todd RF, Reinherz EL, Schlossman SF. Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol. 1981; 12:187-225.
-
Major PP, Griffin JD, Minden M, Kufe DW. A blast subclone of the HL-60 human promyelocytic cell line. Leuk Res. 1981; 5(4-5):429-30.
-
Todd RF, Griffin JD, Ritz J, Nadler LM, Abrams T, Schlossman SF. Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leuk Res. 1981; 5(6):491-5.
-
Spangler GJ, Griffin JD, Rubin H, Livingston DM. Identification and initial characterization of a new low-molecular-weight virus-encoded T antigen in a line of simian virus 40-transformed cells. J Virol. 1980 Nov; 36(2):488-98.
-
Griffin JD, Spangler G, Livingston DM. Enzymatic activities associated with the SV40 large T antigen. Cold Spring Harb Symp Quant Biol. 1980; 44 Pt 1,:113-22.
-
Griffin JD, Spangler G, Livingston DM. Protein kinase activity associated with simian virus 40 T antigen. Proc Natl Acad Sci U S A. 1979 Jun; 76(6):2610-4.
-
Kriegler MP, Griffin JD, Livingston DM. Phenotypic complementation of the SV40 tsA mutant defect in viral DNA synthesis following microinjection of SV40 T antigen. Cell. 1978 Aug; 14(4):983-94.
-
Griffin JD, Light S, Livingston DM. Measurements of the molecular size of the simian virus 40 large T antigen. J Virol. 1978 Jul; 27(1):218-26.
-
Griffin JD, Aisenberg AC, Long JC. Lymphocytic thymoma associated with T-cell lymphocytosis. Am J Med. 1978 Jun; 64(6):1075-9.
-
Griffin JD, Ellman L, Long JC, Dvorak AM. Development of a histiocytic medullary reticulosis-like syndrome during the course of acute lymphocytic leukemia. Am J Med. 1978 May; 64(5):851-8.
-
Griffin JD, Ellman L. Epsilon-aminocaproic acid (EACA). Semin Thromb Hemost. 1978; 5(1):27-40.
-
Griffin JD, Szaro RP, Weltman JK. Ouabain antagonism of smooth muscle contraction. J Pharmacol Exp Ther. 1972 Sep; 182(3):378-87.
-
Coleman AW, Coleman JR, Griffin JD, Weltman JK, Chapman KM. Methylxanthine-induced escalation: a propagated wave phenomenon observed in skeletal muscle developing in culture. Proc Natl Acad Sci U S A. 1972 Mar; 69(3):613-6.
This graph shows the total number of publications by year.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
|
Griffin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|